SGLT2 inhibitors

Lenahan, Christy McDonald; Harrington, Deedra; Stueben, Frances

doi:10.1097/01.npr.0000753832.85114.65

Cited by 8 publications

(6 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Improving heart failure symptoms work by targeting both the preload and the after-load; the former will be regulated by the decrease in plasma volume, whereas the latter is decreased by lower blood pressure, ultimately leading to better cardiac flow. On the other hand, SGLT2i work by reducing arterial stiffness via relaxation of the smooth muscle cells 32 . Patients hospitalized for acute heart failure were usually excluded from clinical trials on SGLT2i.…”

Section: Sodium-glucose Cotransporter 2 Inhibitors In Acute Heart Fai...mentioning

confidence: 99%

See 1 more Smart Citation

Performance of sodium-glucose cotransporter 2 inhibitors in cardiovascular disease

Khater,

Malakouti,

Khoury

et al. 2024

Journal of Cardiovascular Medicine

View full text Add to dashboard Cite

Aims The use of sodium-glucose cotransporter 2 inhibitors (SGLT2i) as a new class of drug in treating type 2 diabetes has expanded beyond its original framework. Positive results have been achieved in reducing symptoms in patients with cardiovascular disease (CVD). The aim of this article is to present an in-depth review of the basic principles of this class of medications and how it has brought benefits to patients affected particularly by heart failure. Methods Following a thorough PubMed search, this review includes 62 studies published between 2015 and 2023. Keywords searched included ‘sodium-glucose cotransporter 2 inhibitors’, ‘cardiovascular disease’, ‘heart failure’, ‘chronic kidney disease’, and ‘type 2 diabetes’. The most recent and comprehensive data were used. Results Positive results have been achieved in reducing symptoms in patients with CVD. SGLT2 inhibitors have also been shown to be useful in other contexts such as nonalcoholic fatty liver disease (NAFLD) by reducing liver fat accumulation, kidney benefits by improving body weight and vascular endothelium, improving eGFR, and reducing progression to end stage kidney disease (ESKD). SGLT2 inhibitors are also effective in reducing the need for heart failure hospitalizations and the risk of serious cardiac adverse events, including cardiovascular and all-cause mortality, in patients with reduced or preserved left ventricular (LV) ejection fraction and in acute or decompensated settings. Conclusion SGLT2 inhibitors have evolved into metabolic drugs because of their multisystem action and are indicated for the treatment of all spectrums of heart failure, type 2 diabetes, and chronic kidney disease.

show abstract

Section: Sodium-glucose Cotransporter 2 Inhibitors In Acute Heart Fai...mentioning

confidence: 99%

“…On the other hand, SGLT2i work by reducing arterial stiffness via relaxation of the smooth muscle cells. 32 Patients hospitalized for acute heart failure were usually excluded from clinical trials on SGLT2i.…”

Section: Action Of Sodium-glucose Cotransporter 2 Inhibitors In Heart...mentioning

confidence: 99%

Performance of sodium-glucose cotransporter 2 inhibitors in cardiovascular disease

Khater,

Malakouti,

Khoury

et al. 2024

Journal of Cardiovascular Medicine

View full text Add to dashboard Cite

show abstract

“…11 The use of SGLT2 inhibitors can be expensive and nurses can provide support by referring patients to the drug manufacturer for financial and copay assistance. 12 Lastly, the nurse should review nonpharmacologic treatment such as a low-sodium diet, exercise as tolerated, and if appropriate, cardiac rehabilitation.…”

Section: Implications For Nursing Carementioning

confidence: 99%

“…Additionally, patients should report any rashes, changes in vaginal or penile discharge, anal itching, pain, swelling or discoloration of the genitals, as this could indicate that the patient is experiencing a fungal infection or is developing Fournier gangrene, a necrotizing fasciitis in the genital area 11. The use of SGLT2 inhibitors can be expensive and nurses can provide support by referring patients to the drug manufacturer for financial and copay assistance 12. Lastly, the nurse should review nonpharmacologic treatment such as a low-sodium diet, exercise as tolerated, and if appropriate, cardiac rehabilitation.…”

Section: Implications For Nursing Carementioning

confidence: 99%

Emerging treatment of heart failure

Tait¹

2023

Nursing Made Incredibly Easy!

View full text Add to dashboard Cite

show abstract

“…Furthermore, studies have shown that in patients with heart failure with reduced and preserved ejection fraction, regardless of type 2 diabetes, SGLT2 inhibitors can minimize disease progression, hospitalizations, and deaths from all causes. 7,8 Nonetheless, the mechanism of SGLT2 inhibitors in cardiovascular protection is complex and warrants further study. Outside of phase III studies, there is limited information concerning the characterization of each agent and the situations where each one would stand out as the better option, especially in Latin America.…”

Section: Introductionmentioning

confidence: 99%

Challenges of Sodium-glucose Transporter-2 Inhibitors Use in a low Socioeconomic Setting

Cruz,

Frías-Ureña,

López

et al. 2023

MRAJ

View full text Add to dashboard Cite

Background: Sodium-glucose transporter-2 (SGLT2) inhibitors have shown efficacy in reducing major adverse cardiovascular events and hospitalizations for heart failure in patients with type 2 diabetes mellitus and concomitant heart failure. Aim: To compare the short-term effectiveness between empagliflozin and dapagliflozin. Methods: A single-center observational cohort study was implemented in a Dominican tertiary-care center, where patients with heart failure and reduced ejection fraction were divided into two groups and treated with different SGLT2 inhibitor molecules, empagliflozin and dapagliflozin. Two-step cluster analysis was conducted for the interim analysis of the study. Results: We enrolled a total of 60 patients, with a median age of 69. The majority of these were men (70%) and comprised 75.0% of the Dapagliflozin 10 mg group and 62.5% of the Empagliflozin 10 mg group. Most participants (61.7%) were categorized as NYHA-II in functional class. The main cause of heart failure was ischemic (55%), while the predominant state of the disease was chronic with 65% patients in this group. Conclusion: This preliminary manuscript evaluated the effectiveness of SGLT2 inhibitors in a Dominican heart failure patient cohort, finding notable gender, age, and risk factor variations, and emphasizing the need for standardized research methods in future investigations.

show abstract

SGLT2 inhibitors

Cited by 8 publications

References 29 publications

Performance of sodium-glucose cotransporter 2 inhibitors in cardiovascular disease

Performance of sodium-glucose cotransporter 2 inhibitors in cardiovascular disease

Emerging treatment of heart failure

Challenges of Sodium-glucose Transporter-2 Inhibitors Use in a low Socioeconomic Setting

Contact Info

Product

Resources

About